Everest Medicines Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,707	706.68	125.93	12.79	0.05
Revenue Growth (YoY)	141.51%	461.16%	884.46%	23588.89%	-
Cost of Revenue	524.78	177.79	34.41	4.65	0.02
Gross Profit	1,182	528.89	91.52	8.15	0.03
Selling, General & Admin	1,057	758.15	396.57	603.23	440.83
Research & Development	511.04	528.04	540.05	809.74	613.43
Other Operating Expenses	227.76	22.92	6.16	-0.12	-4.96
Operating Expenses	1,796	1,309	942.78	1,413	1,049
Operating Income	-613.96	-780.21	-851.27	-1,405	-1,049
Interest Expense	-	-22.19	-23.06	-5.59	-4.81
Interest & Investment Income	-	95.21	107.67	38.48	28.88
Earnings From Equity Investments	-39.15	-	-	-	-
Currency Exchange Gain (Loss)	-	19.51	-28.07	-155.18	22.94
Other Non Operating Income (Expenses)	68.22	2.65	2.82	-1.61	-6.46
EBT Excluding Unusual Items	-584.89	-685.03	-791.91	-1,529	-1,009
Gain (Loss) on Sale of Investments	-13.47	-0.01	0.85	-21.75	-
Gain (Loss) on Sale of Assets	-	-	-1.43	1,320	-
Asset Writedown	-	-356.34	-51.97	-16.49	-
Pretax Income	-598.36	-1,041	-844.46	-247.28	-1,009
Income Tax Expense	-300.6	-	-	0.01	-
Net Income	-297.77	-1,041	-844.46	-247.28	-1,009
Net Income to Common	-297.77	-1,041	-844.46	-247.28	-1,009
Shares Outstanding (Basic)	335	321	313	298	293
Shares Outstanding (Diluted)	335	321	313	298	293
Shares Change (YoY)	4.25%	2.51%	5.18%	1.49%	243.61%
EPS (Basic)	-0.89	-3.24	-2.70	-0.83	-3.44
EPS (Diluted)	-0.89	-3.24	-2.70	-0.83	-3.44
Free Cash Flow	-156.57	-744.92	-886.53	-1,512	-839.89
Free Cash Flow Per Share	-0.47	-2.32	-2.83	-5.08	-2.86
Gross Margin	69.25%	74.84%	72.67%	63.69%	57.41%
Operating Margin	-35.97%	-110.41%	-675.97%	-10981.12%	-1943096.30%
Profit Margin	-17.45%	-147.36%	-670.57%	-1933.11%	-1867998.15%
Free Cash Flow Margin	-9.17%	-105.41%	-703.97%	-11817.36%	-1555344.44%
EBITDA	-478.29	-670.04	-795.72	-1,391	-1,043
EBITDA Margin	-28.02%	-94.82%	-	-	-
D&A For EBITDA	135.67	110.17	55.55	13.81	6.21
EBIT	-613.96	-780.21	-851.27	-1,405	-1,049
EBIT Margin	-35.97%	-110.41%	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.